PathoQuest Raises $5M in Series B Round, Plans Clinical Trial of NGS-based Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) — PathoQuest, an infectious disease diagnostics startup based in Paris, has raised €3.8 million ($5 million) in a Series B private equity funding round, the company said today.

The firm, a 2010 spin-out from the Pasteur Institute and the Ecole Nationale Veterinaire d'Alfort, will use the funding for a clinical trial of a diagnostic assay it has been developing that combines next-generation sequencing and a cloud-based analysis software service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.